Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

NCT04981691 | Unknown Phase 1

• 1 other identifier: Amaretto
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

Conditions

Refractory Malignant Solid Neoplasm

Keywords

Mesothelin; Refractory Solid Tumors; Chimeric Antigen Receptor T-Cell; Phase I clinical trial

Outcome Measures

Primary Outcomes (4)

• TEAEs

  Incidence of Treatment Emergent Adverse Event

  4 weeks after the last infusion

• TRAEs

  Incidence of Treatment Related Adverse Events

  4 weeks after the last infusion

• SIAEs and SAEs

  Incidence of AEs of Special Interest and Serious Adverse Events

  4 weeks after the last infusion

• DLTs

  Incidence of dose-limiting toxicities

  4 weeks after the last infusion

Secondary Outcomes (14)

• TEAEs,TRAEs, SIAEs and SAEs

  12 weeks after the last infusion

• ORR by IR

  12 weeks after the last infusion

• ORR by IRC

  12 weeks after the last infusion

• DCR by IR

  12 weeks after the last infusion

• DCR by IRC

  12 weeks after the last infusion

Other Outcomes (1)

• mesothelin expression and efficacy

  12 weeks after the last infusion

Study Arms (1)

anti-MESO CAR-T cells

EXPERIMENTAL

The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated. Interventions: * Drug: anti-MESO CAR-T cells * Drug: Fludarabine * Drug: Cyclophosphamide

Biological: anti-MESO CAR T cells

Interventions

anti-MESO CAR T cells BIOLOGICAL

Autologous genetically modified anti-MESO CAR T cells

anti-MESO CAR-T cells

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and the willingness to provide written informed consent.
• Advanced pancreatic cancer, ovarian cancer, malignant mesothelioma, gastric cancer, bowel cancer, etc., diagnosed by histopathological or cytological examination, but not limited to subjects with various advanced solid tumors.
• IHC test showed Mesothelin positive expression at least 1+ in tumor tissue
• Age no less than 18 years.
• Life expectancy greater than 3 months.
• According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, there must be measurable lesions.
• Evidence of metastatic disease and failure of at least 1 prior chemotherapy for metastatic disease. During the last treatment or after the treatment, the disease progressed and was confirmed (the investigator judged according to the RECIST 1.1 standard).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 during the screening period and before apheresis.
• Adequate liver/bone marrow function.
• Female subjects must meet the following conditions: infertility or fertility and use high-efficiency contraceptive measures.
• Male subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last study treatment infusion.

You may not qualify if:

• Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to entry into the study.
• Received any anticancer medication in the 2 weeks prior to receiving their first dose of study treatment, including but not limited to surgery, systemic chemotherapy, radiotherapy, intervention, etc.
• Uncontrolled thyroid dysfunction (serum thyroid hormone determination TT4, TT3, FT3, FT4, and serum thyroid-stimulating hormone TSH) are not suitable for enrolling in the study;
• Pregnant or breastfeeding female, or not willing to take contraception measures during the study.
• Any uncontrollable active infection, including but not limited to active tuberculosis; HBV infection (including HBsAg positive, or HBcAb positive and HBV DNA positive); HIV, syphilis, hepatitis C positive or suffering from other fatal viruses, Bacterial disease
• Administrated with steroids (5 mg/day or more dexamethasone, or equivalent hormone drugs) within the past two weeks;
• Other uncontrolled diseases may cause abnormal death of the patient;
• Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks.
• Previously allergic to immunotherapy, tocilizumab, cyclophosphamide, fludarabine, and other related drugs, previous history of severe allergies, to research product excipients (such as human serum albumin, DMSO, and dextran 40 ); people who have a history of penicillin allergy and have a positive skin test at the time of screening.
• Congestive heart failure, uncontrolled cardiac arrhythmia, etc.
• Uncontrollable massive ascites, that cannot be drained by standard methods;
• Intestinal obstruction or CT suggesting omental cake-like peritoneal metastasis, or repeated uncontrollable incomplete intestinal obstruction.
• Have received any genetic engineering modified T cell therapy (including CAR T, TCR T cell).
• Uncontrolled brain metastasis or mental illness.
• Suffered from other uncured malignant tumors within the past 3 years or at the same time.

Sponsors & Collaborators

• Ruijin Hospital: lead
• UTC Therapeutics Inc.: collaborator

Study Sites (1)

Department of Oncology, Ruijin Hospital

Shanghai, 200025, China

RECRUITING

Study Officials

• Jun Zhang, MD, PhD

  Ruijin Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jun Zhang, MD, PhD

CONTACT

0086-13818332497; junzhang10977@sjtu.edu.cn

Yan Shi, MD, PhD

CONTACT

0086-13810561979; sy_rjh@aliyun.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of Department of Oncology

Study Record Dates

• First Submitted: July 7, 2021
• First Posted: July 29, 2021
• Study Start: October 1, 2021
• Primary Completion: January 9, 2022
• Study Completion: July 9, 2022
• Last Updated: September 17, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)